SERPINA4 and type 2 diabetes mellitus: While the mechanistic association between Kallistatin and AD pathogenesis remains uncharacterized in the existing literature, emerging evidence posits Kallistatin as a pivotal molecular mediator bridging neurodegenerative pathology and metabolic dysregulation, potentially orchestrating the pathophysiological crosstalk between AD and T2DM.